Immune checkpoint inhibitors block the interaction between immune checkpoints, such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and their corresponding ligands on cancer cells. This evidence concerns the gene PDCD1 and cancer.